News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Novartis Corporation To Warn US Doctors On Gleevec Heart Risks
October 3, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Oct 3 (Reuters) - Swiss drugmaker Novartis will send a letter to U.S. doctors in the next few days to warn that there is a risk that its cancer drug Gleevec could cause heart damage, a spokesman said.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Insights
Beyond equity: Why venture debt is reshaping European biotech
October 8, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Insights
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
October 5, 2026
·
6 min read
·
Jennifer C. Smith-Parker
Insights
After COVID, biomanufacturing tackles preparedness and commercialization challenges
September 25, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Job Trends
Growth mode: 3 biotechs that are staffing up after series B raises
September 24, 2026
·
3 min read
·
Angela Gabriel